j Abstract The mechanisms that are responsible for the development of myocardial fibrosis in inflammatory cardiomyopathy are unknown. We have previously generated lines of transgenic mice with cardiac-restricted overexpression of tumor necrosis factor (MHCsTNF mice), a proinflammatory cytokine. The MHCsTNF mice develop a heart failure phenotype that is characterized by progressive myocardial fibrosis, as well as increased levels transforming growth factor-b (TGF-b)(mRNA and protein. In order to determine whether TGF-b-mediated signaling was responsible for the myocardial fibrosis observed in the MHCsTNF mice, we treated MHCsTNF and littermate control mice from 4 to 12 weeks of age with a novel orally available TGF-b receptor antagonist (NP-40208). At the time of terminal study, myocardial collagen content was determined using the picrosirius red technique, and left ventricular (LV) systolic and diastolic function were determined using the Langendorff method. Treatment with NP-40208 resulted in a significant (P < 0.05) 65% decrease in nuclear translocation of Smad 2/3, a significant (P < 0.05), decrease in the heart-weight to body-weight ratio from 6.5 to 5.7, a~37% decrease in fibrillar collagen content (P < 0.01) and a significant (P < 0.05) decrease in the LV chamber stiffness by~25% in the MHCsTNF mice when compared to diluent-treated controls. Treatment with NP-40208 had no discernable effect on LV systolic function, nor any effect on cardiac myocyte size or fetal gene expression in the MHCsTNF mice. Taken together, these observations suggest that sustained pro-inflammatory signaling in the adult heart is associated with a pro-fibrotic phenotype that arises, at least in part, from TGF-b-mediated signaling, with resultant activation of Smad 2/3, leading to increased myocardial fibrosis and increased LV diastolic chamber stiffness. j Key words tumor necrosis factor -transforming growth factormyocardial fibrosis -transgenes (MMPs) with subsequent degradation of fibrillar collagen, the mechanisms that are responsible for the progressive myocardial fibrosis that accrues in these mice is not completely understood. Given that TNF inhibits collagen gene expression and/or collagen synthesis in cardiac fibroblasts, [25, 31] the increased myocardial fibrosis observed in transgenic models with cardiac-restricted overexpression of TNF is unlikely to be a direct effect of TNF-mediated signaling. Of note, Feldman and colleagues have suggested the interesting possibility that MMP induced degradation products, or ''matrikines,'' are responsible for the progressive tissue fibrosis in their model of sustained TNF overexpression [17, 18] . A second possible explanation for the increased fibrosis observed in the TNF transgenic mice is that TNF-mediated signaling increases the density of angiotensin type I receptors (AT 1 ) on cardiac fibroblasts, [8] and that this increase in AT 1 receptor density sensitizes cardiac fibroblasts to the pro-fibrotic actions of endogenous angiotensin II [25] . Germane to the present discussion, we have shown that both transforming growth factor-b 1 (TGF-b 1 ) and TGF-b 2 mRNA and protein levels are significantly increased in the hearts of the MHCsTNF transgenic mice relative to littermate controls, raising the interesting possibility that TGF-b-mediated signaling is responsible for the fibrosis observed in the MHCsTNF mice.
In order to determine whether TGF-b-mediated signaling was responsible for the observed myocardial fibrosis observed in the in the MHCsTNF mice, we employed a novel orally available TbRI antagonist, NP-40208 (Scios Inc., Freemont, CA, USA), [21] that blocks TGF-b-mediated signaling by inhibiting the intracellular kinase domain of TbRI. The results of this study suggest that TGF-b-mediated signaling plays an important role in the structural remodeling and cardiac dysfunction that is observed in mice with cardiac-restricted overexpression of TNF.
Methods j Mice
The studies described herein were performed on 12-week-old male mice with cardiac-restricted overexpression of TNF (MHCsTNF) and littermate control mice lacking the TNF transgene. The characterization of the MHCsTNF mice used in these studies has been reported previously [16, 30] . Briefly, MHCsTNF mice develop progressive myocardial fibrosis from 8-12 weeks of age that is characterized by increased levels of TGFb1 and TGFb2 mRNA and protein [30] . All mice housed under standard environmental conditions and maintained on commercial chow and tap water ad libitum. All studies conformed with the principles of the National Institutes of Health ''Guide for the Care and Use of Laboratory Animals,'' and were approved by the Baylor College of Medicine Animal Care and Use Committee.
j TGF-b receptor inhibition
To determine the significance of TGF-b signaling, MHCsTNF and littermate control mice were treated from 4 to 12 weeks of age with diluent or 100 mg/kg body weight/day NP-40208 (Scios Inc., Freemont, CA), a novel 2,4-disubstituted pteridine that inhibits the intracellular kinase domain of the type I TGFb(receptor (TbRI) [21] . In an in vitro kinase assay NP-40208 inhibits the TbRI kinase with an IC50 of 0.048 lmol/L. When tested at 50 nmol/L the compound has no effect on TbRII kinase (data provided by Scios Inc.). The dose of NP-40208 chosen for these studies was based on previous studies which showed that 50-150 mg/kg body weight/day was sufficient to achieve adequate blood levels of NP-40208 (data provided by Scios Inc.). NP-40208 was dissolved in deionized water and administered through drinking water.
j TGF-b-mediated signaling
To determine the specific effects of NP-40208 on TGFb-mediated signaling, we examined protein levels of Smad2/3 in nuclear and cytoplasmic fractions of the MHCsTNF and littermate control mouse hearts. Hearts were excised, snap-frozen in liquid nitrogen and stored at )80 CE until protein extraction. After measuring frozen heart weight, nuclear and cytoplasmic proteins were isolated using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce; Rockford, IL, USA) according to the manufacturer's instructions. Protein levels for Smad2/3 were measured by Western blot analysis as described previously, [22] using a polyclonal Smad2/3 antibody (1:1,000, Upstate, Lake Placid, NY). Western blots were incubated with an appropriate peroxidase-labeled secondary antibody (1:5,000 dilution), and membranes were incubated with luminol using a commercially available kit (ECL plus, Amersham, IL, USA), and exposed to chemiluminescent film. The films were scanned on a personal densitometer (Molecular Dynamics, Sunnyvale, CA, USA) and band intensities were evaluated using ImageQuaNT 4.2a (Molecular Dynamics) software.
j Cardiac morphometrics and myocardial collagen content
Cardiac hypertrophy was assessed by determining the heart-weight to body-weight ratio in littermate con-trol and MHCsTNF mice at 12 weeks of age, as well as by measuring cardiac myocyte cross-sectional area [30] . Myocardial samples were deparaffinized, hydrated, and incubated with Triticum vulgaris Lectin-TRITC conjugate (1:500 dilution, Sigma, St. Louis MO, USA) as described [37] . Nuclei were stained with DAPI (Vector Labs, Burlingame, CA, USA) Myocardial sections (endocardial, mid-myocardial, and epicardial) were examined under 400x magnification (Nikon Eclipse E800, Nikon Inc.) and the cardiac myocyte outline was traced using Metavue software (v6.1, Universal Imaging Corp.). For the analysis of cardiac myocyte cross-sectional area we only examined myocytes that were round to oval in shape, and that had a clearly identified nucleus. A minimum of 100 myocytes were examined at the endocardial, mid-myocardial, and epicardial levels for each treatment group, and the results presented as the average myocyte cross-sectional area.
Myocardial collagen content was determined using the picrosirius red technique, as described [30] . Briefly, after completing the ex vivo studies described below, hearts were perfusion-fixed, embedded in paraffin and stained. The percent area of extracellular picrosirius red staining was computed from three random fields within the mid-myocardium in order to exclude large epicardial arteries and/or veins, as well as any cutting and/or compression artifacts [30] .
j Left ventricular function and stiffness
Hearts from diluent and NP-40208-treated littermate control and MHCsTNF mice were isolated and perfused in the Langendorff mode, as described [27] . Briefly, mice were injected intraperitoneally with heparin (10,000U/Kg; Sigma, St Louis, MO, USA) and anesthetized with Avertin (16 (l/g body weight of a 2.5% solution). The hearts were rapidly excised and perfused in a retrograde manner at a constant perfusion pressure of 80 mmHg with modified KrebsHenseileit buffer containing (mmol): NaCl 118, NaHCO 3 24, KCl 4.7, KH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 2.2, Glucose 11, Pyruvate 2. Buffer was oxygenated with 95% O 2 and 5% CO 2 at 37°C, to yield a pH of 7.4. A thin cannula was pierced through the apex of the LV to vent thebesian drainage. A hand-made balloon (polyvinyl chloride film) connected to a polyethylene tube (PE50), was inserted into the LV through the mitral valve via an incision of the left atrium and was connected to a pressure transducer (ML844, ADinstruments, Colorado Spring CO). The hearts were paced from the right ventricle using a Grass SD9 stimulator (Grass Instruments, Quincy, MA, USA) at 420 beats per minute. Functional data were recorded at 1 KHz on a data acquisition system (PowerLab, ADinstruments, Colorado Spring CO). After 20 min of stabilization, the balloon was progressively inflated in 5-lL increments until LV developed pressure (LVDP) became asymptotic and then began to decline. LVDP was calculated as the difference between peak-systolic pressure and LV end-diastolic pressure (LVEDP). A final pressure-volume exponential relationship obtained as described [9] . The data for LVEDP were plotted as a function of increasing balloon volumes, and were plotted to a best-fit exponential curve (P = bAEexp(KcV)), where V is volume, and P is LV pressure generated for each mouse. The volumes at a given pressure were averaged for animals in each group. The chamber stiffness constant (Kc) was determined by fitting the end-diastolic pressure-volume curves from individual hearts to an exponential function [10, 34] . In order to measure LV systolic function at a physiological filling pressure, the balloon was deflated to adjust LVEDP to 8-10 mmHg, and LV systolic pressure and LVEDP were measured.
j Fetal gene expression
Northern blot analysis was performed on 15 lg of total RNA isolated from the hearts of transgenic mice and littermate control mice [36] . The characterization of the probes for a-myosin heavy chain (a-MHC), bmyosin heavy chain (b-MHC) and SERCA2a has been reported previously [5] .
j Statistical analysis
Results are expressed as mean values ± SEM. Data were assessed with the use of a commercially available statistical software (STATVIEW version 5.0, SAS institute Inc., Cary, NC, USA). Differences at specific time points between groups were assessed using onefactor ANOVA, which was followed by Fisher's PLSD test for post-hoc analysis where appropriate. A P-value <0.05 was considered statistically significant.
Results j TGF-b-mediated signaling
To determine whether there were TGF-b-mediated alterations in Smad 2/3 signaling in the hearts of MHCsTNF mice, we performed Western blot analysis of Smad 2/3 protein levels in cytoplasmic and nuclear extracts. Figure 1 highlights two important findings. First, although the cytoplasmic levels of Smad 2/3 were similar (P = 0.33) in the MHCsTNF and littermate control mice, there was a significant (P = 0.002) increase in the level of Smad 2/3 in the nuclear fraction of the MHCsTNF mouse hearts. The ratio of nuclear to cytoplasmic Smad 2/3 was significantly higher (P = 0.018) in the MHCsTNF mice than in the littermate controls, consistent with activation of TGFb signaling in the MHCsTNF mouse hearts. Second, treatment with the TbRI antagonist NP-40208 significantly attenuated the increase in Smad 2/3 protein in the nuclear fraction compared to diluent-treated MHCsTNF mice, and normalized the ratio of nuclear to cytoplasmic Smad 2/3 of the MHCsTNF mice when compared to diluent-treated littermate controls. However, despite normalization of the nuclear to cytoplasmic ratio in the treated MHCsTNF mice, the absolute level of Smad 2/3 was still significantly greater (P < 0.05) than that observed in the littermate control mice. NP-40208 had no effect on the cytoplasmic nor nuclear distribution of Smad 2/3 in the littermate control mice.
j Cardiac morphometrics Figure 2 shows that the heart-weight to body-weight ratio was significantly greater in the MHCsTNF mice than in the littermate control mice (P < 0.001), consistent with our previous findings [30] . Importantly, treatment with NP-40208 led to a small but significant decrease in the heart-weight to body-weight ratio in MHCsTNF mice (P = 0.016), whereas NP-40208 had no effect on the heart-weight to body-weight ratio in the littermate control mice. However, treatment with NP-40208 did not abrogate cardiac hypertrophy in the MHCsTNF mice, insofar as the heart-weight to bodyweight ratio was still significantly greater than that observed in littermate control mice.
In addition to the heart-weight to body-weight ratio, we also examined myocyte cross-sectional area in diluent and NP-40208-treated MHCsTNF mice and littermate controls. As shown in Fig. 3 , there was no statistically significant (P = 0.33) difference in myocyte cross-sectional area measured at baseline or after Heart weight to Body weight ratio (mg/g) Littermate MHCsTNF * * † Fig. 2 Heart-weight to body-weight ratio in diluent-treated littermate controls (n = 7 hearts), NP-40208-treated littermate controls (n = 6 hearts), diluenttreated MHCsTNF (n = 6) mice, and NP-40208-treated MHCsTNF (n = 6 hearts) mice. (Key *P < 0.05 compared to diluent and NP-40208-treated littermate controls, P < 0.05 compared to diluent-treated MHCsTNF mice) treatment with NP-40208. Moreover, the myocyte cross-sectional area was comparable across endocardial, mid-myocardial, and epicardial regions (data not shown).
j Myocardial collagen content
We have shown that myocardial fibrosis develops in the hearts of the MHCsTNF mice from 8-12 weeks of age [30] . Treatment with NP-40208 attenuated the increase in myocardial collagen content in the MHCsTNF mice at 12 weeks of age (Fig. 4a) . The group data summarized in Fig. 4b , show that treatment with NP-40208 significantly (P = 0.007) attenuated the myocardial collagen content in the MHCsTNF mice when compared to diluent-treated MHCsTNF mice. However, the myocardial collagen content in the NP-40208-treated mice at 12 weeks of age was still significantly greater (P = 0.014) than that observed in the littermate control mice at a comparable time point. Treatment with NP-40208 for 8 weeks resulted in a small, but non-significant decrease in myocardial collagen content in the littermate control mice.
j Myocardial function and stiffness
As shown in the Table 1 , there was no significant difference in LV systolic pressure, LVEDP, nor LVDP in the littermate control and MHCsTNF mice at baseline. Moreover, treatment with NP-40208 had no effect on LV systolic pressure, LVEDP, nor LVDP in the littermate control and MHCsTNF mice. In contrast, Fig. 5 shows that there was a significant increase in diastolic chamber stiffness in MHCsTNF hearts when compared to littermate control hearts, consistent with the increased interstitial myocardial collagen deposition observed in these mice. As illustrated, there was a significant (P < 0.05) leftward shift in the pressure-volume relationship (Fig. 5a) , and a significant (P < 0.05) increase in the LV chamber stiffness constant (Fig. 5b) in the MHCsTNF hearts, when compared to littermate control mice. Consistent with the effects of NP-40208 on myocardial collagen content, treatment with NP-40208 resulted in a rightward shift in the pressure-volume curve in the MHCsTNF mouse hearts when compared to untreated MHCsTNF hearts (Fig. 5a) , as well as a significant reduction (P < 0.05) in the LV chamber stiffness constant (Fig. 5b) . In comparison, treatment with NP-40208 had no effect on the pressure-volume relationship (Fig. 5a ), nor the chamber stiffness constant in the littermate control mice (Fig. 5b) . Importantly, treatment of the MHCsTNF mice with NP-40208 restored LV chamber stiffness to normal. As shown in Fig. 5b LV chamber stiffness in the NP-40208-treated MHCsTNF mice was not significantly different (P > 0.05) from LV chamber stiffness in littermate control mice.
j Fetal gene expression
As shown in Fig. 6 , Serca2a and a-MHC mRNA expression were both reduced, and the expression of b-MHC was increased in MHCsTNF mice when compared to littermate controls. This figure is representative of three separate experiments. Treatment with NP-40208 had no significant effect (P > 0.05) on the level of expression of Serca2a, a-MHC, and b-MHC mRNA in the MHCsTNF mice when compared to diluent-treated controls.
Discussion
The results of this study suggest that TGF-b-mediated signaling contributes to LV structural remodeling (fibrosis) and diastolic dysfunction in mice with cardiac-restricted overexpression of TNF (MHCsTNF). Results of group data for chamber stiffness constant in diluent-treated littermate control (n = 7 hearts), NP-40208-treated littermate control (n = 6 hearts), diluent-treated MHCsTNF (n = 7 hearts), and NP-40208-treated MHCsTNF (P = 6 hearts) hearts.
(Key: LM = littermate; *P < 0.05 compared to diluent and NP-40208-treated littermate controls, P < 0.05 compared to diluenttreated MHCsTNF mice)
The following three lines of evidence support this statement. First, we observed increased nuclear localization of Smad 2/3 protein in the MHCsTNF mice when compared to littermate control mice, consistent with TGF-b induced Smad 2/3 activation (Fig. 1) . Importantly, treatment with NP-40208, a selective TbR1 antagonist, normalized the nuclear to cytoplasmic ratio of Smad2/3 when compared to littermate control mice (Fig. 1) ; however, it bears emphasis that the absolute level of nuclear Smad2/ 3protein was still significantly greater in the NP-40208 mice MHCsTNF when compared to diluent-treated littermate controls, raising the possibility of TGF-bindependent Smad activation in the MHCsTNF mice, as has been reported recently for angiotensin II (reviewed in [26] ). In this regard, we have reported previously that there is increased activation of the renin angiotensin system, as well as increased angiotensin II peptide levels in the hearts of the MHCsTNF mice as they age [7] . That said, we cannot exclude the formal possibility that increased dosage and/or duration of treatment with NP-40208 might have further attenuated nuclear localization of Smad 2/3 in the MHCsTNF mice. Second, we observed that the increased myocardial fibrosis observed in the MHCsTNF mice was sensitive to inhibition with NP-40208 (Fig. 4) . Treatment with NP-40208 resulted in a significant attenuation of myocardial fibrosis in the MHCsTNF mouse hearts when compared to diluenttreated MHCsTNF mice. However, the level of myocardial fibrosis in the NP-40208-treated mice was still significantly greater than that observed in diluenttreated littermate control mice, consistent with the observation that Smad 2/3 nuclear translocation was not completely abrogated by NP-40208. Treatment with NP-40208 resulted in a small but significant decrease in the heart-weight to body-weight ratio of the NP-40208-treated MHCsTNF mice compared to diluent-treated MHCsTNF mice (Fig. 2) , but had no effect on myocyte cross-sectional area (Fig. 3) , suggesting that the observed decrease in the heart-weight to body-weight ratio was secondary to decreased myocardial fibrosis. Finally, treatment of the MHCsTNF mice with NP-40208 for 8 weeks prevented the leftward shift of the pressure-volume relationship, as well as the increased LV chamber stiffness observed in diluent-treated MHCsTNF mice (Fig. 5) . Indeed the values for LV chamber stiffness in the NP-40208-treated MHCsTNF mice were not different from those observed in diluent-treated littermate control mice. Taken together, these observations suggest that sustained pro-inflammatory signaling in the adult heart is associated with a pro-fibrotic phenotype that arises, at least in part, from TbRI-mediated signaling, with resultant activation of Smad 2/3, leading to increased myocardial fibrosis and increased LV diastolic chamber stiffness. Interestingly, treatment with NP-40208 had no discernable effect on expression of the fetal gene pattern observed in the MHCsTNF mice (Fig. 6) ; taken together with the absence of a discernable effect of NP-40208 on myocyte cell area these data suggest that the major pathophysiological role of TGF-b signaling in the MHCsTNF mice involves remodeling of the extracellular matrix. Nonetheless, we cannot exclude a potentially important role of TGF-b on endothelial cells, resident cardiac stems cells and/or hematopoietic cells.
j TGF-b signaling and myocardial fibrosis
Transforming growth factor-b provokes a classical set of transcriptional responses that define the ''profibrotic'' phenotype, including increased myofibroblast transformation, increased collagen synthesis and decreased collagen degradation [19] . Indeed several studies have demonstrated that TGF-b promotes collagen synthesis and/or deposition in cultured cardiac fibroblasts in vitro [1, 3, 29] . Moreover, TGF-b antagonism with neutralizing antibodies, soluble TGF-b receptors, and overexpression of decorin or dominant negative TGF-b receptors has demonstrated that tissue fibrosis can be attenuated in a variety of different tissues including the heart [11, 15, 35] . Further, expression of Smad7, an endogenous inhibitor of TGF-b induced signaling, attenuates experimentally induced lung and kidney fibrosis [23, 33] . Taken together, these observations suggest that sustained activation of TGF-b can lead to pathological tissue fibrosis and/or tissue dysfunction in a variety of organs, including the heart. The results of the present study both complement and extend these previous studies by showing for the first time that an orally available TbR1 antagonist, NP-40208, is sufficient to attenuate myocardial fibrosis, as well as decrease myocardial stiffness in the adult heart. Further, the present study provides provisional evidence that in- [6] the Rho/Rho-kinase signaling pathway, [12] and connective tissue growth factor [4, 24] .
Although TGF-b-mediated signaling has been shown to be important in myocardial fibrosis, it is worth noting a recent study in transgenic mice with cardiac-restricted overexpression of a constitutively active TGF-b 1 mutant, which showed that the expression of this constitutively active mutant did lead to the development of ventricular fibrosis [20] . Moreover, fibrosis was not observed in hearts engrafted with skeletal myoblasts expressing high levels of TGF-b 1 [13] . While these latter two observations do not necessarily obviate a potentially important role for TGF-b as a mediator of cardiac fibrosis, they do suggest that TGF-b per se may be insufficient to promote fibrosis in the adult heart, and that the profibrotic actions of TGF-b may be the result of important time-dependent interactions between TGFb and the complex milieu of growth factors and inflammatory cytokines (TNF, IL-1b) that are expressed following tissue injury. Germane to the present discussion, we have shown previously that the myocardial fibrosis observed in the MHCsTNF mice is sensitive to treatment with losartan, an angiotensin type 1 receptor antagonist [7] . These latter observations are consistent with the point of view that TGF-b may be one of several important mediators that act in concert during the development of progressive myocardial fibrosis that occurs in the setting of sustained pro-inflammatory signaling.
In summary, this study suggests that the TGF-b pathway plays an important role in the development of the progressive myocardial fibrosis and LV chamber stiffness that occurs in the setting of sustained pro-inflammatory signaling. The results of the present study also raise the interesting possibility that the TGF-b pathway may represent a therapeutic target in inflammatory cardiomyopathies. 
